Lung Cancer Screening

USPSTF recommends annual LDCT for adults aged 50-80 years with a 20 pack-year smoking history who currently smoke or quit within the prior 15 years. Discontinue screening after 15 years of abstinence or when a health problem substantially limits life expectancy or ability or willingness to undergo curative lung surgery. PubMedPubMedScreening for Lung Cancer: US Preventive Services Task ...

Screening is for asymptomatic people. Patients with new or worsening cough, hemoptysis, dyspnea, chest pain, unexplained weight loss, hoarseness, focal bone pain, headache, or other potentially cancer-related symptoms should undergo diagnostic evaluation rather than enter a screening workflow, regardless of whether they meet age and smoking criteria. PubMedPubMedScreening for Lung Cancer: CHEST Guideline and Expert Panel Report

The American Cancer Society differs from USPSTF by recommending annual LDCT for asymptomatic adults aged 50-80 years with at least 20 pack-years who currently smoke or formerly smoked, without a quit-year cutoff. ACS also advises against screening when comorbidity substantially limits life expectancy. PubMedPubMedScreening for lung cancer: 2023 guideline update from the American Cancer Society - PubMed

In the NLST, three annual LDCT examinations versus chest radiography reduced lung cancer mortality by 20%; approximately 3 lung cancer deaths were prevented per 1,000 screened. PubMedPubMedScreening for Lung Cancer: CHEST Guideline and Expert Panel Report Across eight randomized trials, pooled evidence showed a 19% relative reduction in lung cancer mortality, corresponding to 4 fewer lung cancer deaths per 1,000 screened. PubMedPubMedScreening for Lung Cancer: CHEST Guideline and Expert Panel Report

Benefit is concentrated in patients with sufficient lung cancer risk and life expectancy to realize a mortality advantage. In NLST risk strata, the number needed to screen to avert one lung cancer death was 161 in the highest-risk quintile versus 5,276 in the lowest-risk quintile. PubMedPubMedScreening for Lung Cancer: CHEST Guideline and Expert Panel Report

LDCT detects many nodules that do not represent cancer. In NLST, 39.1% of LDCT participants had a nodule identified by the end of the screening period. Appropriate nodule protocols avert much unnecessary invasive testing, but screening increases procedures and procedure-related harms relative to control strategies. PubMedPubMedScreening for Lung Cancer: CHEST Guideline and Expert Panel Report

A high-quality shared decision-making encounter determines eligibility, confirms absence of potentially cancer-related symptoms, assesses overall health and willingness to pursue treatment, and explains expected benefit, annual follow-up, potential findings, downstream testing, radiation exposure, and smoking cessation. PubMedPubMedScreening for Lung Cancer: CHEST Guideline and Expert Panel Report

Decision aids improve knowledge and reduce decisional conflict, although available evidence has not shown a consistent increase in screening intention or completion. PubMedPubMedScreening for Lung Cancer: CHEST Guideline and Expert Panel Report The encounter can be performed by trained program personnel or ordering clinicians, but workflow must ensure that responsibility for counseling, orders, results, and follow-up is explicit. PubMedPubMedScreening for Lung Cancer: CHEST Guideline and Expert Panel Report

Programs should use low-radiation chest CT protocols, structured reporting, and a predefined threshold for findings requiring evaluation. CHEST suggests defining a positive result by a solid or part-solid nodule threshold of 4, 5, or 6 mm; Lung-RADS uses a 6-mm baseline threshold and a 4-mm threshold for a new solid nodule on annual screening. PubMedPubMedScreening for Lung Cancer: CHEST Guideline and Expert Panel Report

A positive screening result is a finding that triggers evaluation beyond routine annual screening; it does not imply malignancy. For small nodules, serial imaging is generally the central strategy. Larger solid nodules, enlarging nodules, and suspicious subsolid nodules require malignancy-risk assessment and may warrant PET imaging, nonsurgical biopsy, or resection when appropriate. PubMedPubMedScreening for Lung Cancer: CHEST Guideline and Expert Panel Report

Programs should have access to multidisciplinary pulmonary, radiology, thoracic surgery, medical oncology, and radiation oncology expertise. This is particularly important for nodules with intermediate or high cancer probability and for subsolid lesions, where indolent biology and overdiagnosis must be considered. PubMedPubMedScreening for Lung Cancer: CHEST Guideline and Expert Panel Report

CHEST recommends that screening programs provide evidence-based tobacco cessation treatment to patients who currently smoke. PubMedPubMedScreening for Lung Cancer: CHEST Guideline and Expert Panel Report In a meta-analysis of four trials, participants undergoing LDCT screening had higher quit rates than usual-care participants, with a relative risk of 1.22 and an absolute increase of 33 quitters per 1,000; the optimal cessation intervention within screening programs remains uncertain. PubMedPubMedScreening for Lung Cancer: CHEST Guideline and Expert Panel Report

Offer cessation treatment at the initial screening discussion and reinforce it after results. Screening does not replace cessation, and a negative LDCT should not be framed as evidence that smoking is safe. PubMedPubMedScreening for Lung Cancer: CHEST Guideline and Expert Panel Report